The January 2026 biopharma market outlook makes the case for optimism, citing scaled innovation, supportive valuations, strong M&A momentum, and improving capital markets—trends clearly reflected in biopharma deal and licensing activity tracked by DealForma. Read it here

The 2026 biopharmaceutical M&A and VC outlook shows a rebound in deal activity driven by renewed M&A, more flexible deal structures, and shifting venture investment patterns—trends also reflected in the licensing and transaction data tracked by DealForma. Read it here

Biopharma’s biggest 2025 deals were driven by China-sourced assets, surging interest in bispecific antibodies, and rapid growth in AI-enabled drug discovery — trends highlighted and quantified using DealForma data. Read it here

Stifel’s biopharma market update outlines key trends shaping the sector, including market performance, M&A activity, policy developments, and therapeutic growth areas, using data in part from DealForma.. Read it here

The J.P. Morgan Q3 2025 biopharma and medtech report, using DealForma data, highlights mixed venture investment trends, strong M&A activity, modest IPO recovery, and continued focus on large, late-stage licensing deals across both sectors. Download the biopharma and medtech reports here

DealForma’s analysis, cited by John Carroll, shows Eli Lilly led big pharma in licensing deal activity for Q3 2025, followed by Novartis, Roche, Novo Nordisk, and AstraZeneca. Read it here

Biopharma dealmaking and investment activity rebounded in Q3 2025, signaling potential recovery for the sector after a prolonged downturn, as highlighted in a two-part Endpoints special featuring analysis by DealForma CEO Chris Dokomajilar. Read it here

Stifel’s latest report highlights a surge in biotech momentum, driven by M&A activity, easing rates, and renewed investor confidence—featuring RNA therapeutics as a major innovation focus—with select data provided by DealForma. Read it here

Raveena Bhambra tracked the largest licensing and M&A deals of the first half of 2025. DealForma was happy to help. Read it here

Explore Q2 2025 trends in biopharma and medtech venture funding, M&A and licensing deals. Download the latest J.P. Morgan reports for comprehensive insights and analysis – powered by DealForma. Download them here

Chinese biopharma received 28% of global upfront licensing payments through June 2025. Amber Tong, Jinshan Hong, and Spe Chen cover the latest shift in drug development and biopharma deals from China. Biopharma deal data from DealForma. Read it here

Biotech dealmaking remains strong in 2025, fueled by licensing, M&A, and a surge in AI-driven agreements. The article features several DealForma charts that break down these trends across healthcare, therapeutics, and medtech. Read it here